Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01185 (
vasopressin
)
23,126
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A fundamental challenge in developing treatments for
autism
spectrum disorders is the heterogeneity of the condition. More than one hundred genetic mutations confer high risk for
autism
, with each individual mutation accounting for only a small fraction of cases
1-3
. Subsets of risk genes can be grouped into functionally related pathways, most prominently those involving synaptic proteins, translational regulation, and chromatin modifications. To attempt to minimize this genetic complexity, recent therapeutic strategies have focused on the neuropeptides oxytocin and
vasopressin
4-6
, which regulate aspects of social behaviour in mammals
7
. However, it is unclear whether genetic risk factors predispose individuals to
autism
as a result of modifications to oxytocinergic signalling. Here we report that an
autism
-associated mutation in the synaptic adhesion molecule Nlgn3 results in impaired oxytocin signalling in dopaminergic neurons and in altered behavioural responses to social novelty tests in mice. Notably, loss of Nlgn3 is accompanied by a disruption of translation homeostasis in the ventral tegmental area. Treatment of Nlgn3-knockout mice with a new, highly specific, brain-penetrant inhibitor of MAP kinase-interacting kinases resets the translation of mRNA and restores oxytocin signalling and social novelty responses. Thus, this work identifies a convergence between the genetic
autism
risk factor Nlgn3, regulation of translation, and oxytocinergic signalling. Focusing on such common core plasticity elements might provide a pragmatic approach to overcoming the heterogeneity of
autism
. Ultimately, this would enable mechanism-based stratification of patient populations to increase the success of therapeutic interventions.
...
PMID:Rescue of oxytocin response and social behaviour in a mouse model of autism. 3281 89
Oxytocin (OXT) and
arginine-vasopressin
(
AVP
) are structurally homologous peptide hormones synthesized in the hypothalamus. Nowadays, the role of OXT and
AVP
in the regulation of social behaviour and emotions is generally known. However, recent researches indicate that peptides also participate in cognitive functioning. This review presents the evidence that the OXT/
AVP
systems are involved in the formation of social, working, spatial and episodic memory, mediated by such brain structures as the hippocampal CA2 and CA3 regions, amygdala and prefrontal cortex. Some data have demonstrated that the OXT receptor's polymorphisms are associated with impaired memory in humans, and OXT knockout in mice is connected with memory deficit. Additionally, OXT and
AVP
are involved in mental disorders' progression. Stress-induced imbalance of the OXT/
AVP
systems leads to an increased risk of various mental disorders, including depression, schizophrenia, and
autism
. At the same time, cognitive deficits are observed in stress and mental disorders, and perhaps peptide hormones play a part in this. The final part of the review describes possible therapeutic strategies for the use of OXT and
AVP
for treatment of various mental disorders.
...
PMID:The role of oxytocin and vasopressin dysfunction in cognitive impairment and mental disorders. 3283 7
Intellectual and social disabilities are common comorbidities in adolescents and adults with MAGEL2 gene deficiency characterizing the Prader-Willi and Schaaf-Yang neurodevelopmental syndromes. The cellular and molecular mechanisms underlying the risk for
autism
in these syndromes are not understood. We ask whether
vasopressin
functions are altered by MAGEL2 deficiency and whether a treatment with
vasopressin
can alleviate the disabilities of social behavior. We used Magel2 knockout mice (adult males) combined with optogenetic or pharmacological tools to characterize disease modifications in the vasopressinergic brain system and monitor its impact on neurophysiological and behavioral functions. We find that the activation of
vasopressin
neurons and its projections in the lateral septum are inappropriate to perform a social habituation/discrimination task. Mechanistically, the lack of
vasopressin
impedes the deactivation of somatostatin neurons in the lateral septum, which predicts social discrimination deficits. Correction of
vasopressin
septal content by administration or optogenetic stimulation of projecting axons suppressed the activity of somatostatin neurons and ameliorated social behavior. This preclinical study identifies
vasopressin
in the lateral septum as a key factor in the pathophysiology.
...
PMID:Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model. 3323 6
Developmental exposure to selective serotonin reuptake inhibitor (SSRI) increases the risk of
Autism
Spectrum Disorder (ASD), however, the underlying neurobiology of this effect is not fully understood. Here we used the socially monogamous prairie vole as a translational model of developmental SSRI exposure. Paired female prairie voles (
n
= 20) were treated with 5 mg/kg subcutaneous fluoxetine (FLX) or saline (SAL) daily from birth of the second litter until the day of birth of the 4th litter. This design created three cohorts of FLX exposure: postnatal exposure in litter 2, both prenatal and postnatal exposure in litter 3, and prenatal exposure in litter 4. Post-weaning, subjects underwent behavioral testing to detect changes in sociality, repetitive behavior, pair-bond formation, and anxiety-like behavior. Quantitative receptor autoradiography was performed for oxytocin,
vasopressin
1a, and serotonin 1a receptor density in a subset of brains. We observed increased anxiety-like behavior and reduced sociality in developmentally FLX exposed adults. FLX exposure decreased oxytocin receptor binding in the nucleus accumbens core and central amygdala, and
vasopressin
1a receptor binding in the medial amygdala. FLX exposure did not affect serotonin 1A receptor binding in any areas examined. Changes to oxytocin and
vasopressin
receptors may underlie the behavioral changes observed and have translational implications for the mechanism of the increased risk of ASD subsequent to prenatal SSRI exposure.
...
PMID:Developmental Fluoxetine Exposure Alters Behavior and Neuropeptide Receptors in the Prairie Vole. 3330 47
<< Previous
1
2
3
4
5
6
7
8
9
10